Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)
National Institutes of Health
Inicia sesión y completa tu Funding Passport para ver si calificas — un veredicto transparente basado en reglas, no una caja negra.
Iniciar sesiónSobre esta oportunidad
The purpose of this Funding Opportunity Announcement (FOA) is to support collaborative research projects designed to address adverse sequelae of cancer therapies that persist and become chronic comorbidities or develop as delayed posttreatment effects. This FOA supports basic, translational, and clinical research projects that seek to identify the mechanisms of therapy-induced adverse sequelae, clinically characterize the adverse sequelae, or translate the mechanistic understanding into therapeutic approaches to prevent or minimize the development of long-term sequelae. Research projects should focus on mechanistic studies with translational endpoints and longitudinal clinical phenotyping to identify and validate clinical endpoints (biomarkers, imaging, patient-reported outcomes, or combined elements) for future use in clinical trials that will evaluate the efficacy of interventions designed to prevent or reduce specific adverse sequelae.
Documentos requeridos
La fuente oficial no indica documentos específicos aquí — confirme los requisitos antes de postular.
Fuente y trazabilidad de verificación
- Fuente oficial
- U.S. Federal Government (Grants.gov) ↗
- Primera obtención
- 20 de noviembre de 2026
- Última verificación
- 20 de noviembre de 2026
- Huella del contenido
595c18a936f6d861…